El SalvadorTuberculosis profile
Population  2014 6.1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.12 (0.089–0.15) 1.9 (1.5–2.5)
Mortality (HIV+TB only) 0.031 (0.022–0.041) 0.51 (0.36–0.68)
Prevalence  (includes HIV+TB) 3 (1.3–5.5) 49 (21–90)
Incidence  (includes HIV+TB) 2.5 (2.3–2.7) 41 (38–45)
Incidence (HIV+TB only) 0.24 (0.22–0.26) 3.9 (3.6–4.3)
         
Case detection, all forms (%) 87 (80–95)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.33 (0.04–1.2) 0 (0–4.3)
MDR-TB cases among notified pulmonary
TB cases
6 (1–21) 0 (0–6)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 564   134
Pulmonary, clinically diagnosed 215   0
Extrapulmonary 291   2
       
Total new and relapse 2 206    
Previously treated, excluding relapses 14    
Total cases notified 2 220    
Among 2 070 new cases:
173 (8%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 846 (54%) 123 (82%) 976
Laboratory-confirmed RR-/MDR-TB cases     15
Patients started on MDR-TB treatment ***     15
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 173 (98)
HIV-positive TB patients 203 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 171 (84)
HIV-positive TB patients on antiretroviral therapy (ART) 170 (84)
HIV-positive people screened for TB 5 089  
HIV-positive people provided with IPT 1 946  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (93) 2 176
Previously treated cases, excluding relapse, registered in 2013 (76) 17
HIV-positive TB cases, all types, registered in 2013 (69) 203
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 10
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 3.2
Culture (per 5 million population) 20.5
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 5.1
% Funded domestically 94%
% Funded internationally 6%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-29 Data: www.who.int/tb/data